Download video

Clinica Rever 2 1280 70

No views

Video Que Vende

6 days ago

Clinica Rever 2 1280 70

Clinica Rever 2 1280 70

Clinica Rever 2 1280 70
17:54
Clinica Rever 2 1280 70
by Video Que Vende
2025 06 22 195553 VID003
10:50
2025 06 22 195553 VID003
by Central Police Hospital- Department of Surgery
Optimizing the combination of ibrutinib plus venetoclax in CLL
2:46
Optimizing the combination of ibrutinib plus venetoclax in CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
9 2 medicaltools
2:45
9 2 medicaltools
by Trang Đinh Văn
Full Case Secondary Scleral Sutured IOL Fixation
15:31
Full Case Secondary Scleral Sutured IOL Fixation
by Phaco Dr Kiên (billionaire😍)
Medicine (90281-99607) I Special Otorhinolaryngologic Services (92502-92700) I
9:25
Medicine (90281-99607) I Special Otorhinolaryngologic Services (92502-92700) I
by MECOpedia
CLL12: ibrutinib
1:37
CLL12: ibrutinib
by VJHemOnc – Video Journal of Hematology \& HemOnc
Updates from the Phase II trials of glofitamab and epcoritamab for R\/R LBCL
1:49
Updates from the Phase II trials of glofitamab and epcoritamab for R\/R LBCL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Ramdisk 5 5c OK
2:33
Ramdisk 5 5c OK
by Dr. Linh
How to Simplify Dosing: Understanding Y-90 Dosimetry from Simple to Complex | Tumor Board Ep. 2
53:00
How to Simplify Dosing: Understanding Y-90 Dosimetry from Simple to Complex | Tumor Board Ep. 2
by BackTable Tumor Board
20210228222207
6:19
20210228222207
by Dr. Linh
NKT2152, an oral HIF-2α inhibitor, in pre-treated advanced clear cell renal carcinoma
1:31
NKT2152, an oral HIF-2α inhibitor, in pre-treated advanced clear cell renal carcinoma
by VJOncology
20221005101252
15:18
20221005101252
by Dr. Linh
Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trials
2:00
Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trials
by VJHemOnc – Video Journal of Hematology \& HemOnc
Phase II study of acalabrutinib, venetoclax, and obinutuzumab in CLL enriched for high-risk disease
2:12
Phase II study of acalabrutinib, venetoclax, and obinutuzumab in CLL enriched for high-risk disease
by VJHemOnc – Video Journal of Hematology \& HemOnc
Y90 Dosimetry for HCC Tumors of Varying Size
8:40
Y90 Dosimetry for HCC Tumors of Varying Size
by BackTable Vascular \& Interventional
BXCL701 plus pembrolizumab in 2L advanced PDAC
0:59
BXCL701 plus pembrolizumab in 2L advanced PDAC
by VJOncology
Chemistry Help: Two reactions and their equilibrium constants are given: A+2B↔2C, K1=2.65, 2C↔D, K2
5:22
Chemistry Help: Two reactions and their equilibrium constants are given: A+2B↔2C, K1=2.65, 2C↔D, K2
by Calculus Physics Chem Accounting Tam Mai Thanh Cao
Challenging Case of Multifocal HCC (Part 2): Tumor Response, Re-Treatment?
5:29
Challenging Case of Multifocal HCC (Part 2): Tumor Response, Re-Treatment?
by BackTable Vascular \& Interventional
When and why should I bring up side effects with my doctor? #CLL
1:03
When and why should I bring up side effects with my doctor? #CLL
by HealthTree University for Blood Cancers